Stock analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
Shares of GLMD stock remained flat at $0.39 during trading on Thursday. The company had a trading volume of 22,429 shares, compared to its average volume of 261,749. Galmed Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $7.80. The business has a fifty day moving average price of $0.36 and a two-hundred day moving average price of $0.38.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its quarterly earnings data on Thursday, April 4th. The biopharmaceutical company reported ($0.98) EPS for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Articles
- Five stocks we like better than Galmed Pharmaceuticals
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- MarketBeat Week in Review – 4/29 – 5/3
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Health Care Stocks Explained: Why You Might Want to Invest
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
